The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 501–600 of 1,004
He, S., Chen, Y., Wang, H., Li, S., Wei, Y., Zhang, H., Gao, Q., Wang, F., & Zhang, R.-J. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.018 · Cited by 25
Li, K., Zhao, L., Xing, W., & Tang, Q. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02200-2 · Cited by 25
Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective
Wijers, A., Ravi, A., Evers, S., Tissingh, G., & van Mastrigt, G. A. P. G. (2024) · Movement Disorders · doi:10.1002/mds.29995 · Cited by 29
PINK1 is a target of T cell responses in Parkinson’s disease
Williams, G. P., Freuchet, A., Michaelis, T., Frazier, A., Tran, N. K., Lima-Júnior, J. R., Phillips, E. J., Mallal, S. A., Litvan, I., Goldman, J. G., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180478 · Cited by 34
Autonomic dysfunction in neurodegenerative disease
Mather, M. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00911-8 · Cited by 28
α-Synuclein pathology and mitochondrial dysfunction: Toxic partners in Parkinson's disease
Mingo, Y. B., Galvis, M. L. E., & Henderson, M. X. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106889 · Cited by 30
Barker, R. A., Lao–Kaim, N. P., Guzman, N. V., Athauda, D. S., Bjartmarz, H., Björklund, A., Church, A., Cutting, E., Daft, D., Dayal, V., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02567-2 · Cited by 26
Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges
Zhang, Q., Zhang, W., Yuan, X., Peng, X., & Hu, G. (2025) · Biomedicines · doi:10.3390/biomedicines13071553 · Cited by 29
Vishnumukkala, T., Nassir, C. M. N. C. M., Hein, Z. M., Gopalakrishna, P. K., Karikalan, B., Alkatiri, A., Jagadeesan, S., Naik, V. R., Thomas, W., Moklas, M. A. M., et al. (2025) · Cells · doi:10.3390/cells14191497 · Cited by 30
Clinical milestones in Parkinson's disease: Past, present, and future
Marsili, L., & Mahajan, A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120082 · Cited by 25
Waist circumference and risk of Parkinson’s disease
Park, K., Nam, G. E., Han, K., Park, H.-K., & Hwang, H. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00353-4 · Cited by 27
Pang, H., Yu, Z., Yu, H., Chang, M., Cao, J., Li, Y., Guo, M., Liu, Y., Cao, K., & Fan, G. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13959 · Cited by 25
Jiang, Z., Wang, J., Sun, G., & Feng, M. (2022) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2022.103784 · Cited by 28
Dose-response meta-analysis on urate, gout, and the risk for Parkinson’s disease
Chang, H., Wang, B., Shi, Y. X., & Zhu, R. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00433-5 · Cited by 25
Motawi, T. K., Al-Kady, R. H., Senousy, M. A., & Abdelraouf, S. M. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00656 · Cited by 25
Mohammad, Khan, U. A., Warsi, M. H., Alkreathy, H. M., Karim, S., Jain, G. K., & Ali, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1188470 · Cited by 27
Objective measurement versus clinician-based assessment for Parkinson’s disease
Guerra, A., D’Onofrio, V., Ferreri, F., Bologna, M., & Antonini, A. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2229954 · Cited by 24
Novel HDAC inhibitors provide neuroprotection in MPTP-induced Parkinson's disease model of rats
Meka, S. T., Bojja, S. L., Kumar, G., Birangal, S., & Rao, C. M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176067 · Cited by 25
Wang, D., Gao, H., Qin, Q., Li, J., Zhao, J., Qu, Y., Li, J., Xiong, Y., Min, Z., Mao, Z., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04881-w · Cited by 25
Investigating the aspect of asymmetry in brain-first versus body-first Parkinson’s disease
Lövdal, S., Carli, G., Orso, B., Biehl, M. L., Arnaldi, D., Mattioli, P., Janzen, A., Sittig, E., Morbelli, S. D., Booij, J., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00685-3 · Cited by 30
Effects of Ginger (Zingiber officinale) on the Hallmarks of Aging
Matin, M., Joshi, T., Wang, D., Tzvetkov, N. T., Matin, F. B., Wierzbicka, A., Jóźwik, A., Horbańczuk, J. O., & Atanasov, A. G. (2024) · Biomolecules · doi:10.3390/biom14080940 · Cited by 28
Li, C., Hui, D., Wu, F., Xia, Y., Shi, F., Yang, M., Zhang, J., Peng, C., Feng, J., & Li, C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1303501 · Cited by 24
Liang, H., Ma, Z., Zhong, W., Liu, J., Sugimoto, K., & Chen, H. (2024) · Phytotherapy Research · doi:10.1002/ptr.8156 · Cited by 27
Fiorenzano, A., Storm, P., Sozzi, E., Bruzelius, A., Corsi, S., Kajtez, J., Mudannayake, J. M., Nelander, J., Mattsson, B., Åkerblom, M., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2410331121 · Cited by 25
Zhang, S., Li, M., Li, Y., Yang, S., Wang, J., Ren, X., Wang, X.-H., Bai, L., Huang, J., Geng, Z., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03258-5 · Cited by 28
Molecular mechanisms and biomarkers in neurodegenerative disorders: a comprehensive review
Ali, N., Sayeed, U., Shahid, S. M. A., Akhtar, S., & Khan, M. K. A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10463-w · Cited by 26
Santos‐García, D., Baña, R. M. Y., Labandeira, C. M., Hernando, M. I. C., Cabo, I., González, J. M. P., Losada, M. G. A., Palmás, M. J. G., Bartolomé, C. C., & Miró, C. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080798 · Cited by 24
Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson’s Disease
Zhong, M., Gu, R., Zhu, S., Bai, Y., Wu, Z., Jiang, X., Shen, B., Zhu, J., Pan, Y., Yan, J., et al. (2021) · Behavioural Neurology · doi:10.1155/2021/3469706 · Cited by 26
Dommershuijsen, L. J., Ruiter, R., Erler, N. S., Rizopoulos, D., Ikram, M. A., & Ikram, M. K. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212914 · Cited by 26
Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound?
Stefani, A., Pierantozzi, M., Cardarelli, S., Stefani, L., Cerroni, R., Conti, M., Garasto, E., Mercuri, N. B., Marini, C., & Sucapane, P. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.846681 · Cited by 23
Mitochondrial Respiratory Chain Dysfunction—A Hallmark Pathology of Idiopathic Parkinson’s Disease?
Flønes, I. H., & Tzoulis, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.874596 · Cited by 24
Ni, J.-Y., Zhang, X., Wang, M.-Y., Yu, Q., Sun, R., Xu, Y.-J., Song, Y., & Ge, J. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132065 · Cited by 24
Luengos, I. S., Lucas‐Jiménez, O., Ojeda, N., Peña, J., Gómez‐Esteban, J. C., Gómez‐Beldarrain, M. Á., Vázquez-Picón, R., Foncea, N., & Ibarretxe‐Bilbao, N. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03187-y · Cited by 29
Implication of Paraprobiotics in Age-Associated Gut Dysbiosis and Neurodegenerative Diseases
Rahman, Z., & Dandekar, M. P. (2022) · NeuroMolecular Medicine · doi:10.1007/s12017-022-08722-1 · Cited by 25
Research progress in the early diagnosis of Parkinson’s disease
Xie, L., & Hu, L. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06316-0 · Cited by 23
Wang, Q., Ma, R., Liu, P., Cheng, G., Yang, Q., Chen, X., Wu, Z., Yuan, D., & Chen, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081731 · Cited by 24
Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease
Wilhelm, E., Quoilin, C., Derosière, G., Paço, S., Jeanjean, A. P., & Duqué, J. (2022) · Movement Disorders · doi:10.1002/mds.29214 · Cited by 19
Parkinson’s Disease Gene Biomarkers Screened by the LASSO and SVM Algorithms
Bao, Y., Wang, L., Yu, F., Yang, J., & Huang, D. (2023) · Brain Sciences · doi:10.3390/brainsci13020175 · Cited by 24
Zhou, G., Ren, J., Rong, D., Zhou, H., Ning, H., Wang, H., Pan, C., Wang, Y., Zhang, R., Guo, Z., et al. (2023) · Movement Disorders · doi:10.1002/mds.29366 · Cited by 23
Hesperidin plays beneficial roles in disorders associated with the central nervous system: a review
Atoki, A. V., Aja, P. M., Shinkafi, T. S., Ondari, E. N., & Awuchi, C. G. (2023) · International Journal of Food Properties · doi:10.1080/10942912.2023.2236327 · Cited by 25
Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease
Ren, J., Yan, L., Zhou, H., Pan, C., Xue, C., Wu, J., & Liu, W. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106254 · Cited by 24
Biomarkers of Parkinson’s Disease: From Basic Research to Clinical Practice
Ma, Z.-L., Wang, Z., Zhang, F., Liu, H. P., Mao, L.-H., & Yuan, L. (2023) · Aging and Disease · doi:10.14336/ad.2023.1005 · Cited by 29
Wang, J., Dai, L., Deng, M., Xiao, T., Zhang, Z., & Zhang, Z. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03726-9 · Cited by 24
A role for the subthalamic nucleus in aversive learning
Serra, G. P., Guillaumin, A., Vlcek, B., Delgado-Zabalza, L., Ricci, A., Rubino, E., Dumas, S., Baufreton, J., Georges, F. E., & Wallén‐Mackenzie, Å. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113328 · Cited by 24
Ríos-Urrego, C. D., Rusz, J., & Orozco‐Arroyave, J. R. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01027-6 · Cited by 26
Siah1 in cancer and nervous system diseases (Review)
Zhang, H., Wang, J., Ge, Y., Ye, M., & Jin, X. (2021) · Oncology Reports · doi:10.3892/or.2021.8246 · Cited by 23
Glutamate dehydrogenase: Potential therapeutic targets for neurodegenerative disease
Pan, C., Mao, S., Xiong, Z., Chen, Z., & Xu, N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175733 · Cited by 23
Mendes-Pinheiro, B., Campos, J., Marote, A., Soares‐Cunha, C., Nickels, S., Monzel, A. S., Cibrão, J. R., Loureiro‐Campos, E., Serra, S. C., Barata‐Antunes, S., et al. (2023) · Cells · doi:10.3390/cells12212565 · Cited by 25
Biomaterials and Cell Therapy Combination in Central Nervous System Treatments
Giorgi, Z., Veneruso, V., Petillo, E., Veglianese, P., Perale, G., & Rossi, F. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c01058 · Cited by 23
Augustine, S., Chinnamani, M. V., Mun, C. W., Shin, J., Trung, T. Q., Hong, S. J., Huyen, L. T. N., Lee, E. H., Lee, S. H., Rha, J.-J., et al. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115987 · Cited by 23
Evidence of heat sensitivity in people with Parkinson’s disease
Hunt, A. P., Pagnussat, A. S., Lehn, A., Moore, D. C., Schweitzer, D. R., Laakso, E., Hennig, E. M., Morris, M. E., Kerr, G., & Stewart, I. B. (2024) · International Journal of Biometeorology · doi:10.1007/s00484-024-02658-w · Cited by 23
Han, Z., Yuan, M., Nguyen, N., Zhou, H.-C. “., Hubbard, J. E., & Wang, Y. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215926 · Cited by 23
The role of macrophage plasticity in neurodegenerative diseases
Ma, H., Zhu, M., Chen, M., Li, X., & Feng, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00624-7 · Cited by 24
Akyüz, E., Aslan, F. Ş., Gokce, E., Ilmaz, O., Topcu, F., & Kakac, S. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16541 · Cited by 23
Hopfner, F., Höglinger, G. U., German Parkinson’s Guidelines Group, Bähr, M., Becktepe, J., Berg, D., Brockmann, K., Ceballos-Baumann, A., Claßen, J., Deuschl, C., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12687-5 · Cited by 25
Self-citationSomatic piRNA and PIWI-mediated post-transcriptional gene regulation in stem cells and disease
Patel, M. Z., Jiang, Y., & Kakumani, P. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1495035 · Cited by 24
Small Molecules in Parkinson’s Disease Therapy: From Dopamine Pathways to New Emerging Targets
Lee, H., Elkamhawy, A., Rakhalskaya, P., Lu, Q., Nada, H., Quan, G., & Lee, K. (2024) · Pharmaceuticals · doi:10.3390/ph17121688 · Cited by 23
Unraveling Berberine's Molecular Mechanisms in Neuroprotection Against Neurodegeneration
Begh, M. Z. A., Amin, M. A., Shatu, M. M., Sweilam, S. H., Puri, S., Ramesh, R. B., Arjun, U. V. N. V., Shanmugarajan, T. S., Pommala, N., Durairaj, A., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500170 · Cited by 24
Liu, X., Zheng, Z., Xue, C., Wang, X., Li, J., Liu, Z., Xin, W., Xu, X., Zhou, D., Yao, L., et al. (2025) · Inflammation · doi:10.1007/s10753-025-02291-8 · Cited by 26
Neuropsychiatric disorders in Parkinson’s disease
Heim, B., & Djamshidian, A. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251356062 · Cited by 26
Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems
Lababidi, J. M., & Azzazy, H. M. E.-S. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01081-1 · Cited by 27
Wang, J., Xue, L., Zhang, M., Shen, P., Zhao, W., Tong, Q., Wu, S.-N., Dai, W., Yang, X., & Wang, H. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106086 · Cited by 25
Mitochondrial-Dependent and Independent Functions of PINK1
Chen, X., Wang, Q., Li, S., Li, X., & Yang, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.954536 · Cited by 24
Lahuerta-Martín, S., Llamas‐Ramos, R., & Llamas‐Ramos, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144236 · Cited by 23
Karpodini, C. C., Dinas, P. C., Angelopoulou, E., Wyon, M. A., Haas, A. N., Bougiesi, M., Papageorgiou, S. G., & Koutedakis, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.875178 · Cited by 23
Glycolysis: The Next Big Breakthrough in Parkinson’s Disease
Naeem, U., Arshad, A. R., Jawed, A., Eqbal, F., Imran, L., Khan, Z., & Ijaz, F. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00579-3 · Cited by 23
Nilotinib in Parkinson's disease: A systematic review and meta-analysis
Xie, X., Yuan, P., Kou, L., Chen, X., Li, J., & Li, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.996217 · Cited by 23
Zhu, H., Zhang, H., Hou, B., Xu, B., Ji, L., & Wu, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9110560 · Cited by 22
Wang, Q., Yao, S., Yang, Z.-X., Zhou, C., Zhang, Y., Zhang, L., Zhang, L., Li, J., Xu, Z.-J., Zhu, W.-L., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01039-6 · Cited by 23
Chang, L., Dong, W., Luo, B., Qiu, C., Lu, Y., Lin, X., & Zhang, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14167 · Cited by 23
D2 receptor blockade eliminates exercise-induced changes in cortical inhibition and excitation
Curtin, D., Taylor, E. M., Bellgrove, M. A., Chong, T. T. ‐., & Coxon, J. P. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.04.019 · Cited by 23
Cui, X., Chen, N., Zhao, C., Li, J., Zheng, X., Liu, C., Yang, J., Li, X., Yu, C., Liu, J., et al. (2023) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2023.109884 · Cited by 23
Wang, X., Hu, W., Qu, L., Wang, J., Wu, A., Lo, H. H., Ng, J. P. L., Tang, Y., Yun, X., Wu, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106874 · Cited by 24
Engineering advanced nanomedicines against central nervous system diseases
Shi, S., Ren, H., Xie, Y., Yu, M., Chen, Y., & Yang, L. (2023) · Materials Today · doi:10.1016/j.mattod.2023.08.005 · Cited by 25
Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria
Klein, A. D., & Outeiro, T. F. (2023) · Nature Communications · doi:10.1038/s41467-023-42107-7 · Cited by 23
α-Synuclein pathology from the body to the brain: so many seeds so close to the central soil
Yang, Y., & Zhang, Z. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.387967 · Cited by 27
Huang, Y., Ma, Y., Gao, P., Cui, X.-H., Hou, J., Chi, H., Fu, Y., Wang, Z., Feng, J., Cheng, W., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00633-1 · Cited by 23
Fan, Y., Wang, J., Jian, J., Wen, Y., Li, J., Tian, H., Crommen, J., Bi, W., Zhang, T., & Jiang, Z. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.020 · Cited by 23
Blood-brain barrier biomarkers
Zapata-Acevedo, J. F., Mantilla-Galindo, A., Vargas-Sánchez, K., & González-Reyes, R. E. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.04.004 · Cited by 23
Leveraging ANFIS with Adam and PSO optimizers for Parkinson's disease
Pasha, A., Ahmed, S. T., Painam, R. K., Mathivanan, S. K., Karthikeyan, P. P., Mallik, S., & Qin, H. H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30241 · Cited by 23
Pharmacological PINK1 activation ameliorates Pathology in Parkinson’s Disease modelsPreprint
Hertz, N. T., Chin, R., Rakhit, R., Ditsworth, D., Wang, C., Bartholoméüs, J., Liu, S., Mody, A., Laihsu, A., Eastes, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4356493/v1 · Cited by 23
Li, Y.-J., Leong, I.-I., Fan, J.-Q., Yan, M.-Y., Liu, X., Lu, W.-J., Chen, Y.-Y., Tan, W.-Q., Wang, Y.-T., & Zhuang, L.-X. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1126080 · Cited by 26
The molecular mechanism of ferroptosis and its relationship with Parkinson's disease
Su, Y. R., Jiao, Y., Cai, S., Xu, Y., Wang, Q., & Chen, X. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110991 · Cited by 23
The history and status of dopamine cell therapies for Parkinson's disease
Barker, R. A., Björklund, A., & Parmar, M. (2024) · BioEssays · doi:10.1002/bies.202400118 · Cited by 23
Carrillo, F., Palomba, N. P., Ghirimoldi, M., Didò, C., Fortunato, G., Khoso, S., Giloni, T., Santilli, M., Bocci, T., Priori, A., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106698 · Cited by 22
Cheng, G., Liu, Z., Yan, Z., Wu, J., Li, Z., Gao, S., Zheng, C., Guo, S., Pan, Y., Chen, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.066 · Cited by 22
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases
Xing, C., Chen, H., Bi, W., Lei, T., Hang, Z., & Du, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413446 · Cited by 21
Hypoxia ameliorates neurodegeneration and movement disorder in a mouse model of Parkinson’s disease
Marutani, E., Miranda, M., Durham, T., Kim, S. H., Russell, D. L., Wiesenthal, P. P., Lichtenegger, P., Menard, M. A., Brzozowski, C. F., Li, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02010-4 · Cited by 28
Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy
Wei, S., Zhang, N., Zhang, H., Chen, Z., Li, S., Wu, W., Liu, Z., Xia, Z., Luo, P., & Cheng, Q. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02600-z · Cited by 25
Santos‐García, D., Fernández‐Pajarín, G., Oropesa-Ruiz, J. M., Sevilla, F. E., Rashid-López, R., & Enríquez, J. G. M. (2022) · Brain Sciences · doi:10.3390/brainsci12030383 · Cited by 22
Prediction of Parkinson’s disease based on artificial neural networks using speech datasets
Liu, W., Liu, J., Peng, T., Wang, G., Bălaş, V. E., Geman, O., & Chiu, H. (2022) · Journal of Ambient Intelligence and Humanized Computing · doi:10.1007/s12652-022-03825-w · Cited by 22
Zhao, X., He, H., Xiong, X., Ye, Q., Feng, F., Zhou, S., Chen, W., Xia, K., Qian, S., Yang, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.869797 · Cited by 22
Future Directions in Molecular Imaging of Neurodegenerative Disorders
Barthel, H., Villemagne, V. L., & Drzezga, A. E. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263202 · Cited by 23
Chavarria, D., Benfeito, S., Soares, P., Lima, C., Garrido, J. M. P. J., Serrão, P., Soares-da-Silva, P., Remião, F., Oliveira, P. J., & Borges, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114740 · Cited by 22
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
Rota, S., Urso, D., van Wamelen, D. J., Leta, V., Boura, I., Odin, P., Espay, A. J., Jenner, P. G., & Chaudhuri, К. R. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00317-x · Cited by 22
Yan, R., Cai, H., Cui, Y., Su, D., Cai, G., Lin, F., & Feng, T. (2022) · European Journal of Neurology · doi:10.1111/ene.15651 · Cited by 23
Nango, H., Tsuruta, K., Miyagishi, H., Aono, Y., Saigusa, T., & Kosuge, Y. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00366-w · Cited by 24
Li, Q.-M., Xu, T., Zha, X.-Q., Feng, X., Zhang, F.-Y., & Luo, J.-P. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117196 · Cited by 24
Wu, Y., Wang, J., Deng, Y., Angelov, B., Fujino, T., Hossain, M. S., & Angelova, A. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304588 · Cited by 21
Kowalska, A., Adamska, E., & Grobelna, B. (2024) · ChemMedChem · doi:10.1002/cmdc.202300672 · Cited by 23
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
